

Neuraptive Therapeutics, Inc., a Colorado-based biotech startup, raised \$1 million in a seed funding round led by the **Central Texas Angel Network**, with participation from **New Rhein Healthcare Investors LLC** and several angel investors.

PRESS RELEASE

Lafayette, CO. – August 21, 2017 – Neuraptive Therapeutics, Inc. (Neuraptive) announced today that it has obtained \$1 million in funding. The seed round was led by the Central Texas Angel Network (CTAN) with participation from New Rhein Healthcare Investors LLC (New Rhein) and several angel investors. The Company will use the funds to further develop its flagship product, the AxoFuse Nerve Repair System™ (AxoFuse®) and expand operations.

Improving Peripheral Nerve Repair

When a peripheral nerve is cut or crushed, the patient experiences immediate loss of sensation and function. Traditional surgical nerve repair leads to slow recovery and poor clinical outcomes. Surgical techniques facilitate the natural regeneration process but no current technology can increase the speed or quality of natural nerve regrowth. As a result, patients with peripheral nerve injuries often experience prolonged or permanent disability. Neuraptive aims to improve clinical outcomes for patients with peripheral nerve injuries with AxoFuse®, a novel therapeutic kit for use during nerve repair surgery.

Fusion is the Solution

AxoFuse® utilizes a well-understood method, along with a proprietary drug delivery system, to induce the fusion of cells called PEG-fusion. Previously used in biotech for antibody production, PEG-fusion has been adapted for use in a patient to induce the fusion of recently severed neurons within injured peripheral nerves. This method reconnects the severed axons to dramatically reduce recovery time and significantly improve function compared with the natural regeneration process. Because AxoFuse® leapfrogs contemporary surgical repair it has the potential to revolutionize surgical repair of injured peripheral nerves.

“We are developing a solution to help patients with peripheral nerve injuries and the surgeons that treat them to achieve dramatically better outcomes than what can be expected today. By immediately reconnecting the injured axons, AxoFuse® prevents much of the degeneration of the nerve and limb atrophy that always follow an injury. This allows the potential for the patient to experience a rapid, high-quality recovery from trauma,” said David Jackson, CEO and co-founder of Neuraptive.

Neuraptive is developing AxoFuse® for use in clinical trials. Extensive preclinical data and limited clinical case studies support the hypothesis that AxoFuse® will greatly exceed the standard of care in surgical nerve repair. “This is the first product that maintains the neural network downstream of a peripheral nerve injury - doing so enables significantly faster recovery with better functional outcomes for the patient” said Gino DiSciullo, Board Director. “We believe

this product will change the standard of care in the treatment of peripheral nerve injuries”. The Company intends to present AxoFuse® to US FDA for consent to clinical development within the next six months.

About Central Texas Angel Network (CTAN)

Having invested more than \$88 million in 150+ companies since 2006, CTAN is the #1 most active single-chapter angel group in the nation and is a significant source of early-stage capital to entrepreneurs from Texas and beyond. A member-based nonprofit organization headquartered in Austin, the angel group features more than 170 accredited investors from an extensive cross-section of sectors and backgrounds. CTAN members not only invest; they also mentor entrepreneurs and connect them to business resources, providing critical support to the success of early-stage business and the Texas economy.

Web: www.centraltexasangelnetwork.com

Twitter: @CTANAngels

About New Rhein Healthcare Investors LLC (New Rhein)

New Rhein is a private equity investment firm focused on healthcare therapeutics and medical devices. Its partners and associates are former industry executives with operational and transactional experience.

New Rhein invests in businesses which utilize proven products in new applications (e.g., new indications, new dosage forms, 505(b2)). The company compiles syndicates of operational focused investors who together bring a wealth of experience and a broad network of relationships to support its portfolio companies in development, regulatory, reimbursement, marketing and/or contract manufacturing.

New Rhein provides an understanding on what would be attractive to strategic partners and works backwards to help its portfolio companies build their value proposition. Prior New Rhein investments have included ophthalmic pharmaceuticals, molecular diagnostics and respiratory drug/device inhalers.